Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Niemann Pick Disease

June 1, 2022 CD as API / Pharma applications

Brain uptake and distribution patterns of 2-hydroxypropyl-ß-cyclodextrin after intrathecal and intranasal administration

2-hydroxypropyl-ß-cyclodextrin (kleptose) is used for the treatment of Niemann–Pick disease. Kleptose crosses the blood–brain barrier poorly, in part because of

Continue reading

May 12, 2022 CD as API / Pharma applications

Cothreading of Unmodified and Monoazidated β-Mixed cyclodextrins in polyrotaxanes for Niemann Pick disease

To establish a method for the orthogonal chemical functionalization of β-cyclodextrin (β-CD)-based polyrotaxane (PRX), unmodified and monoazidated β-CDs (N3-β-CDs) were

Continue reading

March 14, 2022 CD as API / Pharma applications

Cyclo Therapeutics on Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C

Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase

Continue reading

January 28, 2022 CD as API / Pharma applications

Combined antioxidants and anti-inflammatory therapies fail to attenuate the early and late phases of cyclodextrin-induced cochlear damage and hearing loss

A major side effect of using high doses of HPβCD to treat Niemann Pick type C (NPC1) disease is sensorineural

Continue reading

January 24, 2022 CD as API / Pharma applications

Time- and frequency-dependent changes in acoustic startle reflex amplitude following cyclodextrin-induced outer and inner cell loss

The acoustic startle reflex (ASR) amplitude can be enhanced or suppressed by noise-induced hearing loss or age-related hearing loss; however,

Continue reading

January 10, 2022 CD as API / Events / Pharma applications

Virtual Public Meeting: Endpoint Considerations to Facilitate Drug Development for Niemann-Pick Type C (NPC)

On January 24-25, 2022, the FDA and Duke-Margolis Center for Health Policy will host a virtual publicworkshop on endpoint considerations

Continue reading

December 21, 2021 CD as API / Pharma applications

Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease

Dec 9, 2021 – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first

Continue reading

September 13, 2021 CD as API / Pharma applications

Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases

The complexity and organization of the central nervous system (CNS) is widely modulated by the presence of the blood–brain barrier

Continue reading

July 30, 2021 CD as API / Pharma applications

Cyclo Therapeutics Inc. Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™

On July 27, the Cyclo Therapeutics, a clinical stage biotechnology firm dedicated to developing life-changing medicines through science and innovation

Continue reading

June 30, 2021 CD as API / Pharma applications

Recent reviews on cyclodextrins against SARS-CoV-2

Recent reviews emphasized the role of membrane lipids in the infectivity mechanism of SARS-COV-2. Cholesterol-rich parts of cell membranes serve

Continue reading

Posts navigation

1 2 3 … 5 Next Posts»

Recent Posts

  • Special issue: Recent Insights in Chemistry and Technology of Cyclodextrins
  • Special issue: Cyclodextrins as building blocks for new materials
  • Matthieu SOLLOGOUB at ICS 20
  • CicloTech®, a new platform to improve trans-ungual drug release
  • Prof. Kohzo Ito at ICS 20

Tags

antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis Trappsol wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (27)
  • CD as API (177)
  • CD derivatives (229)
  • Cosmetics and toilettry (18)
  • Drug delivery (347)
  • E-ducation (49)
  • Environmental (62)
  • Events (149)
  • Food (100)
  • Gene delivery (8)
  • In Hungarian (4)
  • Life sciences (8)
  • Non-pharma applications (166)
  • Other industrial use (51)
  • Pharma applications (586)
  • Supramolecular systems (19)
  • Uncategorized (33)

Top Posts

  • Special issue: Recent Insights in Chemistry and Technology of Cyclodextrins
  • CicloTech®, a new platform to improve trans-ungual drug release
  • How air fresheners work?
  • Matthieu SOLLOGOUB at ICS 20
  • Special issue: Cyclodextrins as building blocks for new materials
  • Use of cyclodextrins as agrochemical delivery system
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • "NON-PHARMA USES OF CYCLODEXTRINS: Food; Nutraceuticals, Environmental and Other Industries, Agriculture” (webinar)
  • ICS2020 in Sicily concluded
  • Prof. Kohzo Ito at ICS 20

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 450 other subscribers

 

Loading Comments...